Skip to main content

ELB011 (Anti-CD160 antibody in ophthalmology)

ELB011 (Anti-CD160 antibody in ophthalmology)

Antibody to treat Age-related Macular Degeneration
Status: Candidate for the clinic selected

ELSALYS BIOTECH has developed a program based on the anti-angiogenic properties of the anti-CD160 antibody to treat vascular eye diseases and in particular Age-related Macular Degeneration (AMD).

Since this therapeutic domain is outside of the strategic field of activity of the company, ELSALYS BIOTECH has signed in 2018 a license option agreement with THÉA Laboratories for the development of its ELB011 program in ophthalmology. As THÉA Laboratories didn't exercise this option, ELSALYS BIOTECH is now open to new partnerships for the clinical development (expected from 2020) and the commercialization of ELB011.

Mechanism of action of ELB011

ELSALYS BIOTECH has already performed preclinical studies with very promising results:

  • In rabbits, treatment with anti-CD160 blocks the formation of new blood vessels, similar to anti-VEGF agents, in a model of induced corneal angiogenesis
  • A combination treatment between an anti-CD160 and an anti-VEGF potentiates the anti-angiogenic effect, suggesting that the two biological pathways are at least partially independent
  • A first generation anti-CD160 limits the number of severe lesions induced with a laser and promotes their healing

Latest news on ELB011

Discover our latest news regarding our pipeline, our partnerships and more

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.